Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel With or Without Cixutumumab in Metastatic Esophageal or GE Junction Cancer
NCT01142388Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2010
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of cixutumumab in esophageal cancer and gastroesophageal junction cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival. Started Sep 2010; status: active, not recruiting.
02
Drugs
cixutumumab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01142388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142388.